(2S)-2-氨基-4-[[(1R)-1-(羧甲基氨基甲酰)-2-(2-羟基丙酰基硫基)乙基]氨基甲酰]丁酸 | 25138-66-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S)-2-氨基-4-[[(1R)-1-(羧甲基氨基甲酰)-2-(2-羟基丙酰基硫基)乙基]氨基甲酰]丁酸
• 英文名称: S-lactoylglutathione
• 英文别名: (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(2-hydroxypropanoylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• CAS: 25138-66-3
• 化学式: C₁₃H₂₁N₃O₈S
• 分子量: 379.391
• InChiKey: VDYDCVUWILIYQF-ALKRTJFJSA-N

物化性质

• 碰撞截面：
  187.7 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  221
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• [EN] BETA LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE LA BÊTA-LACTAMASE
  申请人：ISIS INNOVATION

  公开号：WO2016051133A1

  公开（公告）日：2016-04-07

  A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.

  一种化合物，其为式（I）的硫代醇酸盐或其药用可接受的盐：（I）其中R1、R3、环A1、n和环A2如本文所定义，被发现在抑制金属β-内酰胺酶方面有用，因此可以增强β-内酰胺酶抗生素的活性。该化合物可以单独使用或与式（II）的罗丹啉或其药用可接受的盐结合使用：（II）其中R3、环A1、n、环A2、L和环B如本文所定义。还提供了与β-内酰胺抗生素联合治疗或预防细菌感染。
• INDUCED MALIGNANT STEM CELLS
  申请人：National Cancer Center

  公开号：US20140137274A1

  公开（公告）日：2014-05-15

  PROBLEM There are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells. MEANS FOR SOLVING An induced malignant stem cell capable of in vitro proliferation are characterized by satisfying the following two requirements: (1) having at least one aberration selected from among (a) an aberration of methylation (high or low degree of methylation) in a tumor suppressor gene or a cancer-related genetic region in endogenous genomic DNA, (b) a somatic mutation of a tumor suppressor gene or a somatic mutation of an endogenous cancer-related gene in endogenous genomic DNA, (c) abnormal expression (increased or reduced/lost expression) of an endogenous oncogene or an endogenous tumor suppressor gene, (d) abnormal expression (increased or reduced/lost expression) of a noncoding RNA such as an endogenous cancer-related microRNA, (e) abnormal expression of an endogenous cancer-related protein, (f) an aberration of endogenous cancer-related metabolism (hypermetabolism or hypometabolism), (g) an aberration of endogenous cancer-related sugar chain, (h) an aberration of copy number variations in endogenous genomic DNA, and (i) instability of microsatellites in endogenous genomic DNA in an induced malignant stem cell; and (2) expressing genes including POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

  问题：提供了一种在体外增殖的诱导恶性干细胞，可用于癌症研究和癌症治疗药物发现，以及其生产过程，从这些细胞衍生的癌细胞和这些细胞的应用。 解决方法：一种在体外增殖的诱导恶性干细胞，其特征在于满足以下两个要求： （1）具有来自内源基因组DNA中肿瘤抑制基因或癌症相关遗传区的甲基化异常（高度或低度甲基化），内源基因组DNA中肿瘤抑制基因的体细胞突变或内源性癌症相关基因的体细胞突变，内源性癌基因或内源性肿瘤抑制基因的异常表达（增加或减少/丢失表达），内源性癌症相关microRNA等非编码RNA的异常表达，内源性癌症相关蛋白质的异常表达，内源性癌症相关代谢异常（高代谢或低代谢），内源性癌症相关糖链的异常，内源基因组DNA中拷贝数变异的异常，以及诱导恶性干细胞中微卫星的不稳定性；以及 （2）表达包括POU5F1基因、NANOG基因、SOX2基因和ZFP42基因在内的基因。
• Pyrroloquinoline quinones as enzyme inhibitors
  申请人：Sogo Pharmaceutical Company Limited

  公开号：EP0262345A2

  公开（公告）日：1988-04-06

  The present invention concerns an enzyme inhibitor containing the compound represented by the following formula (I) as an effective ingredient : where R represents hydrogen or substituted or not substi­tuted alkyl group, alkenyl group, aryl group or aralkyl group, X represents ORʹ or NRʺR‴, in which Rʹ, Rʺ and R‴ represent respectively hydrogen or substituted or not substituted alkyl group, alkenyl group, aryl group or aralkyl group. The enzyme inhibitor according to the present inven­tion can effectively inhibit aldose reductase, glyoxalase I and reverse transcriptase.

  本发明涉及一种酶抑制剂，其有效成分含有下式(I)所代表的化合物： 其中 R 代表氢或取代或未取代的烷基、烯基、芳基或芳烷基，X 代表 ORʹ 或 NRʺR‴，其中 Rʹ、Rʺ 和 R‴ 分别代表氢或取代或未取代的烷基、烯基、芳基或芳烷基。 根据本发明的酶抑制剂可以有效地抑制醛糖还原酶、乙醛醛酶 I 和逆转录酶。
• Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
  申请人：Ceres Incorporated

  公开号：EP1033405A2

  公开（公告）日：2000-09-06

  The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3' termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. 0Arabidopsis DNA is used in the present experiment, but the procedure is a general one.

  本发明提供了构成植物基因组片段的 DNA 分子及其编码的多肽。这些 DNA 分子可作为启动子或蛋白质编码序列或 UTR 或 3'终止序列，用于指定细胞中的基因产物，也可用于控制染色体中基因的行为，控制基因的表达，或作为基因绘图、识别或分离相同或相关 DNA 片段、或识别特定生物个体、或对具有共同性状的生物群体进行聚类的工具。 本实验中使用的是拟南芥 DNA，但这是一个通用程序。
• METHOD FOR ENHANCING CATALYTIC ACTIVITY OF CELLS
  申请人：KANSAI CHEMICAL ENGINEERING CO. LTD

  公开号：EP1101818A1

  公开（公告）日：2001-05-23

  Treatment of cells with lower alcohol provides cells having the reaction rate 350 to 600 times higher than that of cells that are not treated with lower alcohol. More specifically, a simple operation of treating cells with lower alcohol provides a catalyst that has a higher activity that that of a cell extract and can be recycled.

  用低度酒醇处理细胞后，细胞的反应速率比未用低度酒醇处理的细胞高 350 到 600 倍。更具体地说，用低度酒醇处理细胞的简单操作就能提供比细胞提取物活性更高的催化剂，并且可以循环使用。